Every drug discovery program has its own challenges. Scientists at Reaction Biology have 20 years of experience in problem-solving and decision making. Via blogs, we like to share some of our experiences and insight into our assays with the drug discovery community to support your journey to a preclinical drug candidate.
Which tumor cell line is best suited for your research? Which lead agents from your library could show promising results in in vivo models? Enter the in vivo hollow fiber model—a groundbreaking tool in preclinical research. How are they developed, and what are their key advantages? Read the blog to find out more!
In the rapidly evolving field of kinase drug discovery, the accurate and efficient evaluation of kinase activity is crucial for identifying potent and selective inhibitors. At Reaction Biology, we offer two assay formats for activity-based kinase screening. In this blog, we compare the assay formats to help you choose the assay that best fits your research needs.
Do you struggle with variable tumor growth in your in vivo models, compromising your research? SubQperior™ offers a superior solution, enhancing tumor growth and consistency for more reliable and impactful results. Ready to elevate your study outcomes? Read the blog to learn more.
While biochemical assays will likely remain a critical entry point for novel molecules into the kinase inhibitor drug discovery pipeline, the field has collectively achieved a state of maturation that increasingly demands priority for cell-based assays right out of the gate.
The fight against cancer continues to evolve, with immunotherapies emerging as a powerful weapon. While initial focus centered on the adaptive immune system, a new wave of therapies targets macrophages, versatile immune cells with a crucial role in the tumor microenvironment (TME).
Kinase inhibitors hold promise for treating diseases like cancer. This blog unveils the multi step process of bringing a drug candidate to market, specifically focusing on lead identification and optimization using an array of biochemical, biophysical, cellular, and in vivo assays. Explore how science transforms promising compounds into potential new treatments.
Immuno-oncology (IO) therapies are revolutionizing cancer treatment, but their complex interactions with the tumor microenvironment pose a challenge in preclinical testing. Enter syngeneic models: how do they differ from traditional models, and how can they be harnessed for IO drug development? Dive into the blog for answers.
Antibody-drug conjugates (ADCs) are emerging as powerful tools in the treatment against cancer. While they hold immense promise for targeted therapy, challenges in efficacy and safety remain. This blog explores the potential and limitations of ADCs, examining their design, function, and ongoing research for a comprehensive understanding of this innovative approach to cancer treatment.
Kinases, the master regulators of cellular signaling pathways, are prime targets for drug discovery. But with so many assays available to measure their activity, how do you choose the right tool for your research? This blog delves into the diverse landscape of kinase assays, empowering you to select the most effective method for investigating your drug targets.
Modelling bladder cancer (BC) for preclinical drug development is notoriously challenging. Due to the route of administration of BC treatments, orthotopic modelling represent the go-to-option for physiological relevance. Here we review current resources for in vivo BC research and describe the characterization of the MB49_luc bioluminescent model.
